- Home
- EFC vs JANX Comparison
EFC vs JANX Comparison
Compare EFC & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFC
- JANX
- Stock Information
- Founded
- EFC 2007
- JANX 2017
- Country
- EFC United States
- JANX United States
- Employees
- EFC N/A
- JANX N/A
- Industry
- EFC Real Estate
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- EFC Finance
- JANX Health Care
- Exchange
- EFC Nasdaq
- JANX Nasdaq
- Market Cap
- EFC 1.4B
- JANX 1.4B
- IPO Year
- EFC 2010
- JANX 2021
- Fundamental
- Price
- EFC $13.21
- JANX $23.41
- Analyst Decision
- EFC Strong Buy
- JANX Strong Buy
- Analyst Count
- EFC 7
- JANX 10
- Target Price
- EFC $14.46
- JANX $79.50
- AVG Volume (30 Days)
- EFC 1.4M
- JANX 613.3K
- Earning Date
- EFC 11-05-2025
- JANX 11-05-2025
- Dividend Yield
- EFC 11.80%
- JANX N/A
- EPS Growth
- EFC N/A
- JANX N/A
- EPS
- EFC 1.24
- JANX N/A
- Revenue
- EFC $312,485,000.00
- JANX $439,000.00
- Revenue This Year
- EFC N/A
- JANX N/A
- Revenue Next Year
- EFC $15.82
- JANX $130.50
- P/E Ratio
- EFC $10.68
- JANX N/A
- Revenue Growth
- EFC 10.76
- JANX N/A
- 52 Week Low
- EFC $11.12
- JANX $21.97
- 52 Week High
- EFC $14.40
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- EFC 38.23
- JANX 45.82
- Support Level
- EFC $13.40
- JANX $23.62
- Resistance Level
- EFC $13.94
- JANX $25.35
- Average True Range (ATR)
- EFC 0.18
- JANX 1.13
- MACD
- EFC -0.08
- JANX 0.04
- Stochastic Oscillator
- EFC 2.67
- JANX 31.45
About EFC Ellington Financial Inc.
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.